Fact-checked by Grok 2 weeks ago

Medical prescription


A medical prescription is a directive issued by a licensed healthcare provider, such as a or , authorizing a to dispense a specific to a for a legitimate therapeutic purpose, typically including details on the drug name, strength, , , and administration instructions. This process ensures that potent or potentially harmful substances are used under professional supervision rather than self-selected by patients.
Prescriptions distinguish between controlled substances, which carry risks of abuse and dependency and thus face stringent federal regulations including scheduling from I to V and mandatory record-keeping, and non-controlled medications with fewer restrictions. In modern practice, systems have largely supplanted paper formats, enhancing efficiency, reducing errors, and enabling real-time verification against patient allergies and interactions, though implementation varies by jurisdiction. Regulations mandate that prescriptions originate from prescribers acting within their professional scope, with pharmacists verifying legitimacy before dispensing to safeguard . While prescriptions facilitate evidence-based treatment and access to specialized therapies, prescribing practices have drawn for instances of overprescribing, particularly in cases leading to , and for vulnerabilities in online platforms where lapses have enabled unauthorized dispensing. These issues underscore ongoing debates over balancing therapeutic benefits with risks of misuse, prompting reforms in monitoring and prescriber accountability.

Definition and Purpose

A , legally, constitutes a written or electronic order issued by a licensed healthcare practitioner to a or dispenser, authorizing the supply of a specified or therapeutic agent to a named for a legitimate medical purpose within the usual course of professional practice. In the United States, under 21 U.S. Code § 829 explicitly defines a valid prescription for controlled substances as one that meets this criterion, requiring the prescriber to be registered with the (DEA) and the order to align with established standards of care to avoid unauthorized distribution. Similar requirements exist in other jurisdictions, such as the United Kingdom's Human Medicines Regulations 2012, which mandate prescriptions for products posing risks without supervision, emphasizing patient-specific dosing and clinical justification to ensure safety and prevent misuse. Clinically, a prescription represents the formal of the prescribing process, wherein a qualified —typically a , dentist, or —evaluates a patient's condition, weighs of against potential adverse effects, and directs the or dispensation of a pharmaceutical tailored to therapeutic needs. This process is grounded in diagnostic assessment and pharmacologic principles, distinguishing prescription medications from over-the-counter alternatives by their requirement for professional oversight due to inherent risks, such as or interactions, as codified in regulatory frameworks like those from the (FDA). Validity hinges on documentation of intent, including drug name, strength, quantity, and instructions, to facilitate accurate fulfillment and monitoring. Distinctions between legal and clinical definitions underscore enforcement mechanisms: while clinical practice prioritizes evidence-based decision-making, legal standards impose penalties for deviations, such as issuing prescriptions outside professional scope, which can result in charges under controlled substances acts. Jurisdictional variances exist; for instance, some countries permit non-physician prescribing under protocols, but core elements—, legitimacy, and specificity—remain universal to mitigate risks from unregulated access.

Rationale for Prescribing

The rationale for prescribing medications centers on achieving therapeutic benefits that demonstrably outweigh potential risks for a diagnosed condition, guided by from clinical trials and pathophysiological understanding. This begins with establishing an accurate through differential evaluation and estimating to define realistic goals, such as curing , reducing symptoms, or preventing progression. Prescribers must select drugs with proven efficacy against the targeted pathology, prioritizing those with favorable pharmacokinetic profiles and minimal adverse effects relative to alternatives. Rational prescribing requires individualized assessment, incorporating patient-specific factors like , comorbidities, concurrent medications, and genetic variations that influence response, to avoid interactions or inefficacy. Non-pharmacological interventions should be considered first or in tandem where evidence supports superior outcomes or lower risks, such as lifestyle modifications for before escalating to . The defines rational use as providing medications appropriate to clinical needs, in doses meeting individual requirements, for an adequate duration, with sufficient information for compliance, thereby minimizing misuse that contributes to or unnecessary harm. Ethical imperatives underpin prescribing, mandating decisions based solely on medical , patient needs, and expected outcomes, while respecting through on benefits, risks, and alternatives. Guidelines emphasize evidence-based selection to maximize effectiveness, reduce adverse events, and optimize resource use, as unsupported prescribing correlates with higher hospitalization rates from errors or . In practice, this involves consulting peer-reviewed data and clinical protocols, avoiding off-label use absent compelling , to align interventions with causal mechanisms of .

Components of a Prescription

Essential Elements and Format

A medical prescription is a written or electronic order from a licensed healthcare provider directing a to dispense a specific to a , incorporating standardized elements to ensure accuracy, legality, and . The traditional format divides the prescription into sections: the superscription (indicated by the symbol , denoting "" or "take"), the inscription (listing the and ), the subscription (instructions to the ), the signature or signa (directions to the ), and the prescriber's and . This structure, rooted in historical pharmaceutical practice, persists in modern prescriptions to facilitate clear communication between prescriber, , and . Essential elements include the prescriber's details, such as name, , telephone number, and professional credentials (e.g., DEA registration number for controlled substances), which must be pre-printed or clearly stated to verify authority and enable contact for clarification. Patient information comprises the full name, , and often date of birth or other identifiers to prevent dispensing errors. The issuance is required to establish validity, as many jurisdictions limit prescription duration (e.g., no more than one year for non-controlled drugs in the U.S.). The core medication details specify the name (preferably with if necessary), strength (e.g., 500 mg), (e.g., tablet, capsule), quantity to dispense, and directions for use (abbreviated as "Sig."), including route (e.g., oral), frequency (e.g., twice daily), and duration. Instructions may also indicate refills (e.g., "refill 3 times") and whether substitutions are permitted (e.g., "dispense as written"). For controlled substances under U.S. (21 CFR Part 1306), additional requirements apply, such as manual signatures on paper or specific , to curb abuse. Prescriptions must be legible, typically written in black ink on secure pads or transmitted electronically via systems compliant with standards like the National Council for Prescription Drug Programs (NCPDP) , which encodes these elements digitally to reduce forgery and errors. Variations exist internationally; for instance, the mandates similar components under Directive 2001/83/EC, emphasizing and . Failure to include any essential element can render a prescription invalid or lead to dispensing delays, underscoring the format's role in and clinical efficacy.

Dosage, Instructions, and Substitutions

The dosage in a medical prescription specifies the amount of the to be administered per dose, the (e.g., oral, intravenous, topical), the frequency of dosing (e.g., once daily, twice daily), and the duration of therapy, all tailored to the patient's condition, age, weight, and to achieve therapeutic efficacy while minimizing adverse effects. These elements are derived from clinical data in the drug's prescribing information, particularly Section 2 (Dosage and Administration), which outlines initial dosing, schedules, and adjustments for renal or hepatic . For instance, antibiotics may prescribe 500 mg every 8 hours for 7-10 days, reflecting evidence from randomized controlled trials establishing dose-response relationships. Instructions for use, denoted by the "Sig" (from Latin signatura, meaning "write") or directions field, provide patient-specific guidance on , often using standardized to ensure clarity and reduce dispensing errors. Common sig codes include "BID" for twice daily, "TID" for three times daily, "QID" for four times daily, and qualifiers like "PC" (post cibum, after meals) or "HS" (hora somni, at bedtime), which help synchronize dosing with circadian rhythms or intake for optimal . The National Council for Prescription Drug Programs (NCPDP) promotes a structured and codified sig format to standardize these instructions electronically, improving and safety by parsing complex directions like "take 1 tablet by mouth every 6 hours as needed for pain, not to exceed 4 doses per day." Substitutions allow pharmacists to dispense a therapeutically equivalent alternative, primarily generics for brand-name drugs, unless the prescriber explicitly prohibits it (e.g., via "dispense as written" or DAW). , all states permit under laws ensuring , as verified by the FDA through average studies showing 80-125% confidence intervals for key pharmacokinetic parameters like area under the curve and maximum concentration. State regulations vary: most operate under an "open" system allowing automatic for FDA-approved unless contraindicated, while others use positive formularies listing substitutable drugs or mandate to control costs, with only 19 states requiring it for brand-name small-molecule drugs when are available. This practice has expanded market share, reducing expenditures, but requires prescriber notation for narrow-therapeutic-index drugs like where minor variations may affect outcomes.

Adaptations for Special Populations

Prescriptions require adjustments for special populations due to physiological differences affecting drug and , such as altered , , , and . These adaptations minimize risks like or subtherapeutic effects, guided by regulatory frameworks including FDA recommendations for dosing in vulnerable groups. In pediatric patients, dosing is typically calculated by body weight (mg/kg) or (mg/m²) to account for immature organ function and rapid growth, with neonates requiring further reductions due to underdeveloped renal and hepatic clearance. The FDA mandates pediatric assessments for drugs intended for children under the Best Pharmaceuticals for Children Act, yet as of 2022, many prescriptions remain off-label because adult trials predominate, leading to extrapolation methods for efficacy and safety data. For instance, doses often start at 50-75% of adult equivalents adjusted for age bands, with monitoring for adverse events heightened in infants. Geriatric patients, particularly those over 65, necessitate dose reductions for drugs with renal elimination given age-related declines in (GFR), averaging a 1 mL/min/1.73 m² annual drop after age 40, alongside hepatic metabolism slowdowns and increased sensitivity to anticholinergics or sedatives. affects over 40% of this group, elevating adverse drug event risks by 2-3 fold, prompting tools like the to flag potentially inappropriate medications such as long-acting benzodiazepines or proton pump inhibitors without indication review. Prescribers emphasize starting low and titrating slowly ("start low, go slow"), with regular deprescribing to address cumulative effects from comorbidities. For renal impairment, doses of renally excreted drugs (e.g., >30% clearance via kidneys) are adjusted using estimated GFR via Cockcroft-Gault or MDRD formulas; severe cases (GFR <30 mL/min) may halve intervals or reduce loading doses to prevent accumulation, as seen with antibiotics like vancomycin where therapeutic drug monitoring targets trough levels of 15-20 mg/L. Hepatic impairment adjustments rely on Child-Pugh scores, recommending reductions for high-extraction drugs like opioids, though guidelines lag due to heterogeneous liver function metrics, with only about 50% of anticancer agents having formal data as of 2023. 00216-4/fulltext) Pregnancy demands risk-benefit assessments, with the FDA's and Labeling Rule (PLLR) replacing prior letter categories to detail fetal risks from human data; teratogenic agents like are contraindicated, while others like certain antihypertensives require trimester-specific dosing to avoid placental transfer issues. In , resources like LactMed® evaluate , advising against drugs with high partitioning (e.g., radioiodine) but permitting most with , as maternal benefit often outweighs low-risk alternatives absent in 2013 AAP reviews.

Prescribing Authority and Practices

Qualified Prescribers

In the , physicians licensed as Doctors of Medicine (MDs) or Doctors of Osteopathic Medicine () hold comprehensive prescriptive authority for all medications, including Schedules II through V controlled substances, as authorized under and state medical boards. This authority requires registration with the () for controlled substances and adherence to state-specific scope-of-practice laws. Advanced practice registered nurses (APRNs), including nurse practitioners (NPs), clinical nurse specialists, certified nurse midwives, and certified anesthetists, possess prescriptive authority in all states, but the extent varies: 27 states and of Columbia grant full independent practice authority as of 2024, allowing NPs to prescribe without oversight, while others mandate collaborative agreements or supervision. Physician assistants (PAs) similarly require delegation in most states, with prescriptive rights limited to the supervising 's scope and often excluding independent Schedule II prescribing without additional protocols. Both APRNs and PAs must obtain registration for controlled substances where authorized. Specialist prescribers include dentists (DDS or DMD), who may prescribe medications for oral conditions, including limited controlled substances like analgesics and antibiotics; optometrists, authorized in 48 states for ocular therapeutics such as antibiotics and steroids; and podiatrists (DPM), who prescribe for lower extremity conditions. Veterinarians () prescribe for animal use only, excluded from human medical prescriptions. Pharmacists hold collaborative or independent prescribing in 49 states for specific scenarios, such as vaccinations, contraceptives, or cessation, but not broadly for therapeutic drugs without protocols. Internationally, prescriptive authority aligns with physicians as the core group but expands variably: in the , nurses and pharmacists gained independent prescribing rights in 2006 for most medications within their competence, regulated by the and General Pharmaceutical Council. By 2021, 44 countries authorized some nurse prescribing, often limited to or chronic conditions, while and permit NPs full authority in designated areas. Midwives prescribe in select nations like for maternity-related drugs. These expansions aim to address provider shortages but require competency assessments and jurisdictional licensing, with controlled substances typically restricted to physicians.

Writing Standards and Error Mitigation


Writing standards for medical prescriptions emphasize clarity, completeness, and legibility to prevent errors that could harm patients. Prescribers are required to include essential elements such as the patient's full name, date of birth, the name ( and if applicable), strength, , quantity, dosing instructions, duration, prescriber's name, , and contact information. Incomplete orders, such as omitting the prescriber's or , substantially increase the risk of errors.
To mitigate errors, organizations like the Institute for Safe Medication Practices (ISMP) recommend avoiding error-prone abbreviations, symbols, and dose designations, such as "U" for units (which can resemble "0"), "" for international units, or trailing zeros in doses (e.g., 5.0 mg instead of 5 mg). Latin abbreviations like "qd" for daily or "qod" for every other day should be spelled out to prevent misinterpretation, as these have contributed to overdoses and underdoses in clinical settings. The (ASHP) advises typing or fully writing out instructions rather than using unapproved shorthand, particularly in hospital settings where handwritten orders persist despite electronic alternatives. Electronic prescribing systems have become a primary , reducing illegibility issues associated with handwriting; the StatPearls review notes that the ISMP endorses eliminating handwritten prescriptions in favor of computerized provider order entry (CPOE) to minimize transcription s. These systems often include built-in checks for drug interactions, allergies, and dosing limits. For look-alike/sound-alike drugs, FDA and ISMP promote tall man lettering (e.g., vs. ) in prescriptions to differentiate names and reduce selection s. Ongoing prescriber training on these standards is essential, with initial and continuous education recommended to foster adherence and awareness of common pitfalls. Pharmacists serve as a final safeguard, verifying prescriptions against standards and clarifying ambiguities before dispensing.

Standing Orders and Non-Standard Prescriptions

Standing orders consist of predefined protocols or directives issued by authorized practitioners, such as , that permit non-physician healthcare personnel—including nurses, medical assistants, and paramedics—to administer medications, perform diagnostic tests, or initiate treatments without obtaining an individualized patient-specific order for each instance. These orders are designed to standardize care in routine or predictable scenarios, enhancing efficiency in environments like clinics, departments, or campaigns where physician oversight may be intermittent. For implementation, standing orders must specify precise criteria, such as patient eligibility, dosage ranges, contraindications, and follow-up requirements, and they require periodic review to align with evidence-based practices. In the United States, federal regulations under the Centers for Medicare & Medicaid Services (CMS) endorse standing orders in hospital settings, mandating their documentation in patient records and authentication by the ordering practitioner to ensure accountability. State-level variations exist; for instance, New York law permits registered nurses to execute non-patient-specific protocols issued by physicians, physician assistants, or nurse practitioners, provided the orders are within the nurse's scope of practice and institutional policies. Similarly, Texas defines standing medical orders as general guidelines for preparatory or procedural acts, applicable across multiple patients when specific directives are absent. Legal risks arise if orders lead to adverse events due to inadequate training or oversight, prompting requirements for practitioner liability coverage and protocol audits. Common applications include nurse-led administration of during seasons—such as the 2023-2024 campaign where standing orders enabled over 170 million doses nationwide—or protocol-driven initiation for suspected urinary tract infections in outpatient settings. Studies indicate standing orders reduce workload by up to 20% in while maintaining care quality, though empirical data emphasize the need for rigorous training to prevent dosing errors, which occur in approximately 5-10% of protocol implementations without safeguards. Non-standard prescriptions extend beyond individualized written orders to include formats like verbal or telephone directives, which are permissible in urgent situations but necessitate prompt written verification—typically within 24-48 hours per standards—to minimize transcription inaccuracies responsible for 12% of medication errors. These differ from standing orders by targeting specific patients temporarily, often in emergencies, and are subject to stricter authentication to uphold chain-of-custody integrity. Protocols for non-standard issuance, such as electronic order sets in hospitals, integrate safeguards like computerized decision support to enforce evidence-based dosing, reducing variability compared to ad-hoc verbal communications. In jurisdictions like , non-standard orders must explicitly address client-specific absences, ensuring they serve as interim measures rather than substitutes for comprehensive evaluation. Empirical reviews highlight that while non-standard methods accelerate access—vital in time-sensitive cases like —they correlate with higher error rates absent double-checks, underscoring causal links to incomplete documentation.

Regulatory Framework

Controlled Substances Regulations

Controlled substances, defined under as drugs or chemicals with potential for abuse, are regulated to prevent diversion while permitting legitimate medical use. , the () of 1970 establishes a framework classifying substances into five schedules based on their potential for abuse, accepted medical use, and safety under medical supervision. Schedule I substances, such as and lysergic acid diethylamide (LSD), exhibit high abuse potential and lack accepted medical use in treatment, rendering them non-prescribable. Schedules II through V include drugs with varying degrees of abuse risk but recognized therapeutic applications, such as opioids (e.g., in Schedule II) and benzodiazepines (e.g., in Schedule IV).
ScheduleCriteriaExamplesPrescription Rules
IHigh abuse potential; no accepted medical use; unsafe for use under medical supervision, marijuana (federally), No prescriptions allowed
IIHigh abuse potential; accepted medical use; high potential for severe dependence, , Written or electronic prescription required; no automatic refills; oral prescriptions must be followed by written confirmation within 7 days; registration mandatory
IIIModerate abuse potential; accepted medical use; moderate dependence riskAnabolic steroids, , Prescriptions allowable with up to 5 refills within 6 months; oral or written
IVLow abuse potential; accepted medical use; low dependence riskXanax (), Valium (), Similar to III; up to 5 refills within 6 months
VLowest abuse potential; accepted medical use; limited dependence riskCough preparations with , Lyrica ()Often over-the-counter in some cases; prescriptions if required
Prescribers authorized to handle controlled substances must obtain a registration, renewed every three years, and comply with security, record-keeping, and reporting mandates to track inventory and dispensing. For Schedule II drugs, prescriptions generally cannot be refilled without a new , and electronic prescribing for controlled substances (EPCS) is increasingly mandated, with the (CMS) requiring at least 70% of qualifying Medicare prescriptions to be electronic by 2025 to curb fraud and errors. Since 2023, DEA-registered practitioners must complete an 8-hour training on opioid or substance use disorder treatment as a registration renewal condition, aimed at addressing the opioid crisis. Telemedicine flexibilities, initially expanded during the , allow Schedule II-V prescriptions without an in-person exam under certain conditions, extended through December 31, 2025, pending permanent rules. Violations, including improper prescribing contributing to diversion, incur penalties enforced by the , ranging from fines to , with heightened scrutiny on high-risk opioids following public health data linking overprescription to dependency epidemics. Internationally, regulations stem from treaties, including the 1961 (amended 1972), which limits narcotic drugs to medical and scientific purposes; the 1971 ; and the 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. These bind signatory nations to schedule substances similarly and control production, trade, and prescriptions, though implementation varies by country—for instance, stricter quotas in under the European Monitoring Centre for Drugs and Drug Addiction framework. National laws, such as the U.S. , align with these treaties but adapt to local contexts, prioritizing of abuse patterns over uniform global standards.

Off-Label and Investigational Use

Off-label use refers to the prescription of a drug for an indication, dosage, route of administration, or patient population not specified in its FDA-approved labeling. In the United States, physicians retain legal authority to prescribe FDA-approved drugs off-label based on their clinical judgment, as federal regulations do not restrict medical practice in this manner, though pharmaceutical manufacturers are prohibited from promoting off-label uses. This practice is prevalent, with studies estimating that 21% to 32% of all prescriptions involve off-label applications, rising to over 50% in specialties like pediatrics and oncology where approved options are limited. While off-label prescribing enables therapeutic innovation and addresses unmet needs, such as in rare diseases, it often proceeds without FDA-reviewed data on and efficacy for the unapproved context. One analysis of prescriptions found that 11% were off-label, of which 79% lacked strong supporting from randomized controlled trials or meta-analyses. Adverse drug events occur at higher rates with off-label use (19.7 per 10,000 person-months) compared to on-label (12.5 per 10,000 person-months), potentially due to insufficient dosing or interaction data. Physicians must weigh these risks, often relying on peer-reviewed literature or clinical experience, and inform patients of the evidentiary basis to mitigate liability under standards. Investigational use involves prescribing unapproved drugs or biologics still under development, typically requiring an Investigational New Drug (IND) application to the FDA before interstate shipment or human administration outside approved marketing. The IND process, governed by 21 CFR Part 312, mandates sponsors to submit preclinical data, manufacturing details, and protocols demonstrating that risks are reasonable relative to anticipated benefits, with FDA authorization needed to initiate clinical investigations. For patients ineligible for trials, expanded access programs—also known as compassionate use—allow investigational drugs for serious or life-threatening conditions when no comparable alternatives exist, provided the potential benefit justifies risks and does not interfere with drug development. These pathways approved over 1,000 individual patient INDs annually in recent years, emphasizing rigorous oversight to protect participants while facilitating access.

International Variations

Medical prescription practices exhibit significant international variations, influenced by national healthcare systems, legal frameworks, and implementation of global treaties such as the of 1961. While hold prescribing authority universally, the scope for non- prescribers differs markedly; for instance, nurses are authorized to prescribe medications in 13 European countries, including , , , , and the , often limited to specific conditions or after additional training. In contrast, countries like and many in restrict independent prescribing primarily to s, with nurses and pharmacists requiring physician oversight for most medications. Pharmacist prescribing authority also varies, with independent prescribing permitted in the , (in certain states), , , , , and , typically for minor ailments or management to alleviate workload. These expansions correlate with efforts to improve access in settings, though evidence from implementation studies indicates reduced hospital referrals in such systems without increased adverse events. In developing nations, such as and parts of , informal over-the-counter dispensing by pharmacists often substitutes for formal prescriptions due to limited regulatory enforcement and shortages, leading to higher risks of misuse. Regulations for controlled substances reflect national interpretations of international schedules, resulting in divergent prescribing thresholds; for example, prescriptions face stricter quantity limits and monitoring post-2016 reforms compared to more permissive access in parts of prior to recent tightening. A 2013 analysis of 23 countries found inconsistencies in classifications, with some nations like imposing triplicate prescribing forms for narcotics to curb diversion, while others rely on electronic tracking. The World Health Organization's 2025 guideline aims to harmonize access to essential controlled medicines for pain relief, addressing under-prescribing in low-income countries where consumption remains below 1% of global totals despite high disease burdens. Electronic prescribing adoption rates highlight technological disparities, with developed nations achieving 80-90% utilization in pharmacies—such as Denmark's near-universal system since 2010—while developing countries lag at 30-40%, constrained by infrastructure and digital literacy. In the European Union, cross-border prescriptions are facilitated under Directive 2011/24/EU, allowing valid use across member states if formatted per national standards, though non-EU travelers must verify import rules varying by destination. Formulary coverage and reimbursement also diverge; high-income OECD countries show wide variation in reimbursed prescription drugs, with public systems in Canada and the UK emphasizing generics to control costs, unlike fee-for-service models in the US that incentivize higher-volume prescribing. These differences underscore causal factors like reimbursement policies and regulatory stringency in shaping utilization patterns, with no single model dominating empirically validated outcomes.

Historical Evolution

Ancient and Pre-Modern Origins

The earliest recorded medical prescriptions originated in ancient around 2100 BC, where clay tablets detailed instructions for compounding herbal remedies and potions to treat ailments such as and digestive disorders. These artifacts represent the transition from oral traditions to written directives, enabling healers—often priests or scribes—to standardize preparations using ingredients like , , and beer, reflecting empirical trial-and-error based on observed outcomes rather than systematic . In , circa 1550 BC, the compiled nearly 700 prescriptions blending empirical remedies with incantations, addressing conditions from eye diseases to using substances such as , , and animal fats applied as ointments or ingested mixtures. This document, alongside others like the , illustrates a causal approach linking symptoms to bodily imbalances, with prescriptions specifying dosages and preparation methods to restore harmony, though efficacy relied on rudimentary testing absent controlled validation. Greek physicians, exemplified by (c. 460–370 BC), shifted toward rational regimens prioritizing diet and lifestyle over , yet the cataloged drug types including purgatives and emetics derived from plants like , prescribed sparingly to avoid disrupting natural healing processes. In , (129–c. 216 AD) expanded this into a comprehensive pharmacopeia, authoring treatises on over 500 simples and compounds—such as , an mixing dozens of ingredients—to balance humors, influencing practice through detailed instructions tested on gladiators and animals. During the (8th–13th centuries), scholars like (Ibn Sina, 980–1037) synthesized Greco-Roman knowledge in works such as the Canon of Medicine, which prescribed tailored formulations of herbs, minerals, and animal products for specific pathologies, emphasizing dosage precision and clinical observation; this text standardized prescriptions across the and later Europe via translations. In medieval Europe (c. 500–1500), prescriptions drew from these sources in monastic and university settings, as seen in 12th-century texts detailing recipes for distillates and salves using and , often inscribed in Latin for apothecaries, though spiritual etiologies coexisted with material remedies. These pre-modern practices laid foundational —linking agent, dose, and effect—but lacked isolation of active principles, leading to variable potency and risks from adulteration.

Modern Standardization and Key Milestones

The establishment of national pharmacopeias in the early 19th century marked a foundational step in standardizing drug preparations, which directly influenced prescription practices by ensuring consistent potency, purity, and nomenclature for compounded medicines. In the United States, the (USP) was founded in 1820 by eleven physicians in , creating the first formal compendium of drug standards to address variability in preparations. Similar efforts occurred internationally, such as the in 1864, which codified drug strengths and formulas to promote uniformity in prescribing and dispensing across the . These compendia reduced reliance on idiosyncratic recipes, enabling prescribers to specify drugs with greater precision and reliability, though enforcement remained decentralized until later regulatory frameworks. The early 20th century saw legislative milestones that formalized prescription requirements for hazardous substances, shifting from voluntary standards to mandatory oversight. The U.S. of 1906 prohibited misbranded or adulterated drugs, mandating accurate labeling and establishing the groundwork for federal inspection, which indirectly standardized prescription instructions by emphasizing verifiable drug contents. Building on this, the of 1914 required prescriptions for and products exceeding exempt thresholds, imposed record-keeping on prescribers and pharmacists, and introduced penalties for non-compliance, marking the first federal distinction between over-the-counter remedies and those necessitating professional oversight. These measures addressed causal risks of unregulated access, such as and , while standardizing documentation to track controlled substances. Mid-century reforms further delineated prescription drugs from non-prescription ones, embedding safety-based criteria into law. The Federal Food, Drug, and Cosmetic Act of 1938 expanded requirements for drug safety testing and labeling, including explicit "Caution: Federal law prohibits dispensing without prescription" for habit-forming substances, prompted by incidents like the disaster that killed over 100 people due to untested solvents. The Durham-Humphrey Amendment of 1951 codified the modern definition of prescription drugs as those unsafe for without supervision, authorizing the FDA to classify medications accordingly and restricting their sale to licensed prescribers' orders only. This binary framework, supported by empirical evidence of misuse risks, standardized global prescribing norms—influencing bodies like the —and reduced variability in what required a written versus self-selection.

Late 20th and Early 21st Century Reforms

The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, established an abbreviated pathway for approvals through new drug applications that relied on demonstrated rather than full clinical trials, thereby expanding access to lower-cost alternatives and comprising over 90% of U.S. prescriptions by volume within decades. This reform balanced innovation incentives by extending patent exclusivity for originator drugs up to five years to offset regulatory review delays. The Prescription Drug Marketing Act of 1988 prohibited the diversion of prescription drugs into illegitimate channels by mandating state licensing for wholesale distributors, restricting reimportation of drugs, and barring the sale or trade of manufacturer samples, measures aimed at curbing counterfeiting and ensuring integrity for prescribers and . Complementing these distribution safeguards, the Omnibus Budget Reconciliation Act of 1990 required pharmacists to perform prospective drug utilization reviews for recipients, screening prescriptions for therapeutic duplications, interactions, incorrect dosing, and clinical abuse, while mandating patient counseling to enhance adherence and safety. Prescription drug monitoring programs proliferated in the and as electronic tools to track prescriptions, with pioneering mandatory electronic reporting in 1990 and 27 additional states implementing programs between 2000 and 2010 to detect and overprescribing patterns. These initiatives, often housed in public safety or departments, provided prescribers with real-time data on histories across pharmacies, contributing to reduced diversion rates in adopting states. The Prescription Drug User Fee Act of 1992 authorized the FDA to collect fees from drug manufacturers to expedite review processes, reducing approval times from an average of 30 months pre-1992 to under 12 months by the early 2000s and facilitating timelier access to new therapies without compromising safety standards. Reauthorized periodically, it addressed backlogs that had delayed prescriptions for innovative treatments. The Food and Drug Administration Modernization Act of 1997 further accelerated approvals, introduced incentives for pediatric studies, and imposed restrictions on promoting unapproved uses, refining the evidentiary basis for prescribing decisions. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 created , offering voluntary outpatient prescription coverage to over 40 million elderly and disabled beneficiaries starting in 2006, with private plans negotiating formularies that influenced prescribing patterns toward cost-effective options. This reform markedly increased medication utilization among seniors, though it initially faced challenges with coverage gaps and premium costs.

Technological Advancements

Transition to Electronic Prescribing

The transition to , or e-prescribing, began gaining legislative momentum in the United States with the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003, which authorized the (CMS) to develop standards for secure electronic transmission of prescriptions under , aiming to reduce medication errors and improve efficiency. This act marked a shift from paper-based systems, which were prone to illegibility and , by promoting between prescribers, pharmacies, and payers through standardized formats. Adoption accelerated following the Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009, part of the American Recovery and Reinvestment Act, which incentivized (EHR) implementation with meaningful use requirements that included e-prescribing capabilities, leading to a surge in usage from 29 million electronically routed prescriptions in 2007 to 68 million in 2008. By 2021, 94% of U.S. prescriptions were filled electronically, with 92% of prescribers utilizing the technology, driven by demonstrated reductions in adverse drug events and time savings for providers. For controlled substances, initial barriers persisted due to security concerns; however, the (DEA) revised regulations in 2010 to permit electronic issuance of Schedules II-V prescriptions, requiring two-factor authentication, digital signatures, and audit trails to prevent diversion while maintaining the prescription in unaltered electronic form. Further updates in 2023 enabled single electronic transfers between pharmacies for these substances, effective August 28, 2023, enhancing patient convenience without compromising chain-of-custody integrity. Globally, transitions have varied by regulatory environment, with early implementations in countries like the United Kingdom via the National Health Service's Electronic Prescription Service in 2005, though comprehensive adoption rates lag behind the U.S. in many regions due to infrastructure disparities and privacy regulations such as the EU's General Data Protection Regulation. In developing systems, challenges including interoperability and digital literacy have slowed progress, contrasting with U.S. incentives that prioritized empirical safety gains over uniform mandates.

Integration with Health Records and AI Tools

Electronic prescribing systems have increasingly integrated with electronic health records (EHRs) to enable seamless access to patient data during prescription processes, reducing manual errors and improving medication reconciliation. In the United States, the Centers for Medicare & Medicaid Services (CMS) reported that EHR-integrated e-prescribing contributes to fewer medical errors by providing real-time visibility into patient histories, allergies, and concurrent medications, with adoption mandated for certain providers under the Medicare Access and CHIP Reauthorization Act of 2015. A 2023 study of outpatient physicians found that such integration streamlines workflows and enhances care quality through automated checks, though inefficiencies arise when systems retrieve only partial patient information. Artificial intelligence (AI) tools further augment this integration by embedding clinical decision support (CDS) directly into EHR workflows, analyzing vast datasets for personalized recommendations and error detection. For instance, AI-driven systems like those from Glass Health provide CDS for differential diagnoses and treatment plans, interfacing with EHRs to flag potential drug interactions or dosing issues based on patient-specific factors. Elsevier's ClinicalKey AI, expanded in 2025, integrates with EHRs to deliver evidence-based insights at the point of care, supporting prescribers in selecting optimal therapies while minimizing overrides of non-actionable alerts. Empirical evidence from a 2024 review indicates AI validation tools reduced prescribing errors by 55% and alert fatigue by 45% through precise filtering. AI applications in prescription management leverage EHR data for , such as forecasting adverse events or optimizing in chronic conditions. A 2025 study highlighted 's role in community pharmacies, achieving a 55% reduction in missed prescription refills via adherence monitoring integrated with EHRs. Similarly, models in CDS systems have demonstrated up to 40% improvements in drug adherence by generating personalized reminders and confirming medication identities. These tools process multimodal EHR inputs, including lab results and , to support causal inferences on drug efficacy, though challenges persist in ensuring model generalizability across diverse populations. Despite these advances, integration faces barriers including data interoperability issues and clinician resistance due to workflow disruptions. A 2024 analysis noted that while AI reduces error incidence, over-reliance without human oversight risks propagating biases from training datasets, necessitating rigorous validation. Ongoing innovations, such as wearable AI for real-time error detection prior to dispensing, aim to address these by enhancing pre-prescription verification. Overall, EHR-AI synergy has empirically lowered prescription-related adverse events, with a 2025 Frontiers in Medicine review attributing gains to AI's precision in decision support over traditional rule-based alerts.

Barriers and Emerging Innovations

Despite widespread recognition of electronic prescribing's benefits, adoption faces persistent barriers, including limited among disparate (EHR) systems and pharmacy software, which disrupts seamless data exchange and contributes to errors in prescription fulfillment. challenges, such as non-intuitive interfaces and excessive alert fatigue from drug interaction warnings, further impede clinician uptake, with studies from 2024 identifying these as primary workflow disruptions in and settings. limitations, including outdated databases and high implementation costs, exacerbate these issues, particularly in smaller practices lacking resources for system upgrades. Integrating with EHRs and prescription tools introduces additional hurdles, notably algorithmic biases arising from unrepresentative training , which can perpetuate disparities in prescribing recommendations across demographic groups. risks from handling sensitive patient , coupled with stringent regulations like HIPAA, demand robust cybersecurity measures that many systems currently lack, leading to potential breaches and eroded . Regulatory fragmentation and the absence of standardized validation for outputs also slow deployment, as evidenced by 2025 analyses highlighting compliance burdens and fragmented silos as key obstacles to scalable AI-driven prescribing. Emerging innovations seek to overcome these barriers through AI-enhanced decision support systems that leverage to predict adverse drug events with greater precision than traditional rules-based alerts, reducing alert fatigue by up to 50% in pilot implementations. Blockchain-based platforms are gaining traction for creating immutable, interoperable prescription ledgers, enabling secure cross-system sharing while addressing concerns via decentralized , as demonstrated in healthcare prototypes since 2022. Standards like (FHIR) are advancing data integration, with 2023 studies showing improved e-prescribing safety through better EHR-pharmacy connectivity. Additionally, hyper-personalized prescribing via analysis of genomic and promises tailored regimens, though full realization depends on resolving ethical and bias mitigation challenges.

Controversies and Challenges

Overprescribing and Abuse Epidemics

Overprescribing of controlled substances, particularly , benzodiazepines, and stimulants, has fueled epidemics of misuse, , and overdose deaths in the United States, with empirical data showing sharp rises in prescriptions correlating to increased non-medical use. From 2006 to 2010, annual opioid prescribing rates climbed from 72.4 to 81.2 prescriptions per 100 persons, peaking amid expanded indications for management despite limited long-term efficacy evidence. By 2019, 9.7 million persons aged 12 and older reported past-year misuse of prescription s, down from prior peaks but still reflecting entrenched diversion and dependency patterns initiated by initial overexposure. Overdose deaths involving prescription , while declining 13.5% from 2017 to 2018, contributed to over 500,000 total opioid-related fatalities since the 1990s, underscoring how liberal dispensing practices created a gateway to broader . The crisis exemplifies causal links between prescribing volume and abuse epidemics, with peer-reviewed analyses identifying overprescribing as a primary driver alongside demand and vulnerabilities. Rates began declining post-2010 due to regulatory interventions like monitoring programs, falling to 46.8 prescriptions per 100 persons by , yet misuse persisted at nearly 8.6 million instances in 2023, often transitioning to illicit . Benzodiazepines parallel this pattern, with 30.6 million adults reporting past-year use in surveys, including 5.3 million (2.2%) misusing them, rates highest among ages 18-25 at 5.2%. Overdose deaths involving prescription benzodiazepines rose 21.8% from April-June to April-June 2020, frequently in polydrug contexts with , highlighting risks from concurrent prescribing without sufficient safeguards. Stimulant medications for attention-deficit/hyperactivity disorder (ADHD) have seen analogous surges, with prescriptions increasing amid diagnostic expansions, leading to diversion and non-medical use epidemics particularly among young adults. In 2023, 14.5% of college students reported misusing prescription stimulants, often for cognitive enhancement or recreation, contributing to a 299% rise in ADHD medication errors from 2000 to 2021. While not yielding overdose fatality rates comparable to opioids, abuse prevalence reached 14.3% in some surveyed populations, with Schedule II classification underscoring high dependence potential despite therapeutic intent. Antibiotic overprescribing, though less tied to personal than epidemics, exemplifies systemic overuse, with at least 28% of outpatient prescriptions deemed unnecessary based on CDC tracking of 236.4 million annual scripts in (709 per 1,000 persons). This equates to 23-30% inappropriate use in ambulatory settings, driven by diagnostic uncertainty and patient expectations rather than microbial confirmation, fostering global without direct addiction parallels. Declines in prescribing during the (up to 33% in outpatient venues) demonstrated feasibility of , yet baseline overuse persists, costing billions in resistance-related morbidity. These epidemics reveal first-principles failures in balancing therapeutic access against risks, with data indicating that initial overreliance on pharmaceutical solutions—absent rigorous outcome —amplified downstream harms, as corroborated by longitudinal CDC surveillance and peer-reviewed syntheses. Interventions like dose limits and have curbed some prescription volumes, but sustained underscores the need for causal interventions targeting initiation phases over reactive containment.

Influence of Pharmaceutical Incentives

The utilizes a range of incentives, including direct financial payments, meals, consulting fees, and promotional detailing visits, to shape physicians' prescribing behaviors. Empirical analyses of U.S. Open Payments data reveal that physicians receiving industry payments prescribe more of the paying companies' , with associations persisting across therapeutic classes; for example, a 2024 study found that such gifts increase prescriptions and elevate overall drug costs by influencing choices toward higher-priced promoted options. A of studies up to 2020 confirmed that payments correlate with increased prescribing volume, higher costs, and preference for the sponsor's products over alternatives. Meta-analyses underscore the robustness of these effects: one aggregating data from six countries reported that pharmaceutical promotion influences prescribing, leading to greater utilization of advertised drugs, often irrespective of clinical superiority. Another meta-analysis of physician-industry interactions estimated an of 2.52 for favorable prescribing shifts following exposure to , based on controlled studies. These patterns hold in recent U.S. data; for instance, neurologists receiving payments related to drugs in 2013–2022 prescribed disproportionately more from high-paying manufacturers, with the top 10% of recipients accounting for 95.2% of $163.6 million in transfers. Direct-to-consumer advertising (DTCA), legal only in the United States and , amplifies these incentives by stimulating demand, which pressures prescribers. Research shows DTCA boosts prescription requests and fulfillment rates, increasing both appropriate and inappropriate utilization; one review linked it to distorted perceptions of benefits over risks, contributing to 12% of U.S. drug spending growth in 2000 via a $4.20 return per . In therapeutic areas like , industry meals alone—totaling millions annually—correlate with higher prescriptions of promoted agents like post-2015 approval. Such incentives contribute to overprescribing and elevated healthcare costs, as evidenced by cross-national comparisons where financial ties favor brand-name drugs over generics, even when is comparable. While some argue promotions enhance awareness of underused therapies, the preponderance of evidence indicates biased decision-making, with limited countervailing effects from disclosure mandates like Open Payments, which have not substantially reduced payment volumes or prescribing shifts since 2013.

Regulatory Burdens vs. Patient Autonomy

Regulatory burdens on medical prescriptions, including requirements and stringent federal oversight, often delay or deny patient access to treatments, conflicting with principles of patient autonomy that emphasize informed decision-making by competent adults. In the United States, —mandatory insurer approvals before prescribing certain drugs—affects continuity of care, with 94% of surveyed reporting delays in necessary treatments and 78% of patients abandoning prescribed therapies due to these hurdles. Such delays have been linked to adverse clinical events, including hospitalizations and worsened health outcomes, as administrative processes consume time—up to 14 hours weekly per AMA surveys—and erode trust in care delivery. FDA drug approval timelines exemplify broader regulatory friction, averaging 10-12 years from discovery to market, during which patients face elevated mortality risks from unaddressed conditions. Analyses indicate that each year of delay in approving effective therapies correlates with thousands of preventable deaths; for instance, modeling of drugs suggests global life-years lost equivalent to one per dozen seconds of regulatory holdup. These timelines, rooted in post-1962 Kefauver-Harris Amendments mandating proof, prioritize but inadvertently paternalize by limiting off-label or investigational uses, despite physicians prescribing off-label in 20-30% of cases without proportional harm . Post-2016 opioid prescribing restrictions, including CDC guidelines capping doses at 90 milligram equivalents daily, reduced prescriptions by over 40% by 2019 but correlated with undertreatment of non-cancer , affecting 50 million U.S. adults. This shift prompted involuntary tapering for stable patients, exacerbating suffering and contributing to a 30% rise in -related suicides from 2015-2020, as access barriers outweighed abuse prevention gains in non-diverted contexts. Efforts to bolster autonomy include the 2018 federal Right to Try Act, enabling terminally ill patients to access investigational drugs bypassing full FDA review after Phase 1 trials, with over 300 requests approved by 2023 without documented excess harms. This framework underscores tensions: while regulations mitigate risks like unproven therapies' inefficacy (seen in 90% of expedited approvals offering marginal benefits), empirical data reveal that excessive gatekeeping—via pharmacy benefit managers or state schedules—disempowers patients, fostering inequities where affluent individuals navigate barriers more readily. Balancing these requires evidence-based deregulation, such as streamlined authorizations via gold-carding compliant providers, to align safety with .

Economic and Societal Impacts

Cost Drivers and Affordability Issues

Prescription drug expenditures reached $722.5 billion in 2023, reflecting a 13.6% increase from , driven primarily by higher prices for -name medications rather than utilization alone. -name drugs account for the bulk of spending despite comprising a minority of prescriptions, with U.S. prices for these drugs averaging 2.78 times higher than in other high-income nations in , a gap widening over time due to limited price during patent-protected periods. Single-source drugs saw average list price increases of 7.4% from January to January 2023, exacerbating overall cost pressures. Key drivers include the need to recoup substantial (R&D) investments, estimated by the at $1 billion to over $2 billion per new when accounting for failed trials and , which patents enable through temporary market exclusivity to incentivize in a high-risk where only about 12% of drugs in clinical testing reach approval. Regulatory exclusivities and patents, lasting up to 20 years plus extensions, prevent generic entry and sustain monopoly , though empirical data show prices drop significantly post-expiry—often by 66% or more within five years—as competition emerges. While some analyses find no direct between firm-level R&D spending and individual drug prices, aggregate U.S. revenues from elevated generate the profits necessary to fund global pharmaceutical R&D, which totaled over $200 billion annually in recent years, with diminished returns potentially curtailing future breakthroughs as observed in price-controlled markets. Affordability challenges manifest in patient behaviors, with 27% of U.S. adults they did not fill prescriptions due to in recent surveys, and 37% of those taking four or more medications citing difficulties affording them. drugs mitigate this by offering average savings of 79% compared to brand-name equivalents, comprising 90% of prescriptions but only 18-20% of expenditures, yet barriers like delayed generic approvals and tactics—filing secondary patents to extend exclusivity—prolong high costs for conditions such as cancer and . Biosimilars similarly reduce prices by about 50% upon market entry versus reference biologics. In , high out-of-pocket costs lead to skipped doses or delayed , with providers noting overwhelmed s rationing therapies, underscoring how fragmented —untethered from direct in programs—amplifies burdens absent robust .

Insurance Dynamics and Reimbursement

Insurance reimbursement for medical prescriptions primarily occurs through pharmacy benefit managers (PBMs), which act as intermediaries between health insurers, pharmacies, manufacturers, and patients, negotiating rebates from manufacturers and determining formulary coverage to control s. PBMs process claims, set reimbursement rates for pharmacies—often below the amount charged to insurers via practices like spread pricing—and retain a portion of rebates, which critics argue inflates net prices despite claims of cost savings for plans. In , PBMs managed benefits for over 270 million covered lives, influencing decisions on preferred drugs and steering patients toward affiliated pharmacies to maximize profits. Formularies tier drugs by cost-effectiveness, with generics in Tier 1 (lowest copays), preferred brands in Tier 2, and non-preferred or specialty drugs in higher tiers requiring prior authorization (PA) or step therapy, where patients must fail cheaper alternatives first. PA processes, intended to ensure medical necessity, delay access for 94% of affected patients and lead to treatment abandonment in 78% of cases, with physicians completing an average of 40 PAs weekly in 2024, contributing to administrative burdens and potential care disruptions. Reimbursement dynamics favor covered drugs, potentially incentivizing prescriptions aligned with formulary incentives over clinical optimality, as uncovered medications result in full out-of-pocket (OOP) costs for patients. In , which covered 51 million enrollees in 2025, beneficiaries face a $590 (rising to $615 in 2026), followed by 25% until reaching the coverage gap, after which catastrophic protection limits to 5% under the amendments. Overall U.S. prescription spending reached $505.7 billion in 2023, representing 10% of national health expenditures, with average annual for beneficiaries at $581, often higher for specialty drugs due to tiering and PA hurdles. These structures, while curbing insurer expenditures through rebates averaging 30-50% on brands, have been linked to opaque pricing where PBM rebates do not fully translate to lower premiums or patient costs, prompting scrutiny and legislative proposals for by 2025.

Recent Policy Interventions and Outcomes

The of 2022 introduced 's authority to negotiate prices for select high-cost prescription drugs, with the first 10 drugs selected for negotiation in August 2023 and maximum fair prices set to take effect in 2026. Provisions effective earlier included capping insulin costs at $35 per month for beneficiaries starting in 2023 and requiring rebates from manufacturers if drug prices rose faster than for Part B and D drugs. The projected these measures would reduce the federal deficit by $237 billion over 2022-2031, with initial estimates of $6 billion in savings for the first negotiated drugs in 2026 alone, representing a 22% spending reduction on those medications. However, empirical outcomes through 2025 remain preliminary, as full price impacts are deferred, and critics note potential disincentives for new due to reduced manufacturer revenues. In response to the opioid crisis, federal and state policies continued to tighten prescribing guidelines, building on prior reductions that saw opioid prescriptions decline 44.4% from 2011 to 2020, including a 6.9% drop from 2019 to 2020. monitoring programs (PDMPs) with mandatory checks and limits on initial doses correlated with decreased prescription opioid misuse and overdose deaths involving prescriptions, but overall opioid-involved overdose deaths rose, driven by a shift to illicit and . A 2021 analysis found that while state-level interventions reduced prescription opioid deaths, they were associated with short-term increases in heroin-related fatalities as users transitioned from diverted prescriptions. By 2023-2024, despite sustained prescribing curbs, U.S. overdose deaths exceeded 100,000 annually, underscoring that supply restrictions alone failed to stem illicit market dynamics. Post-COVID telemedicine flexibilities for prescriptions were extended by the () through December 31, 2025, allowing practitioners to prescribe schedules II-V without an in-person exam under certain conditions, including for up to a six-month initial supply via audio-video. This built on temporary waivers from 2020-2023 that during the public health emergency, with subsequent rules in May and October 2023 preventing a abrupt "policy cliff." Outcomes included sustained utilization for and prescriptions, mitigating access barriers in rural areas, though state variations in rules for controlled substances persisted, and federal oversight emphasized risk assessments to curb diversion. No widespread evidence of increased abuse from these extensions has emerged by 2025, but monitoring continues amid debates over balancing convenience with verification requirements.

References

  1. [1]
    Definition of prescription - NCI Dictionary of Cancer Terms
    Listen to pronunciation. (prih-SKRIP-shun) A doctor's order for medicine or another intervention.
  2. [2]
    Rule 4729:5-5-15 | Manner of issuance of a prescription. - Ohio Laws
    A prescription, to be valid, must be issued for a legitimate medical purpose by an individual prescriber acting in the usual course of the prescriber's ...
  3. [3]
    Pharmacy Prescription Requirements - StatPearls - NCBI Bookshelf
    Prescriptions are written for controlled and noncontrolled medication categories. There are 5 different levels of scheduling for controlled medications (I-V), ...
  4. [4]
    Medical Prescription - an overview | ScienceDirect Topics
    Medical prescription refers to a requirement for certain medicinal products that are likely to present a danger if used without medical supervision, ...
  5. [5]
    Electronic prescription system requirements: a scoping review - NIH
    Sep 3, 2022 · Electronic prescription system requirements: a scoping review ... medical prescription", "Electronic prescription system", "Electronic ...
  6. [6]
    [PDF] 20 CSR 2220-6.050 - Missouri Secretary of State
    Dec 31, 2023 · PURPOSE: This rule establishes procedures for pharmacists to administer medication pursuant to a medical prescription order. (1) A pharmacist ...
  7. [7]
    Controversies and Legal Issues of Prescribing and Dispensing ...
    State medical boards may fine cyberdoctors; however, en- forcement can be difficult because some sites do not reveal the identity or location of the prescribing ...
  8. [8]
    Controversies and Legal Issues of Prescribing and Dispensing ...
    However, online pharmacies have generated controversies, including the use of “cyberdoctors” on some sites, the dispensing of drugs without prescriptions from ...
  9. [9]
    Uncomfortable prescribing decisions in hospitals: the impact of ... - NIH
    Doctors reported 193 uncomfortable prescribing incidents. Evidence-based medicine (EBM), the doctor–patient relationship and the overall healthcare team were ...
  10. [10]
    Barriers and facilitators in nurse prescribing practices - NIH
    Dec 12, 2024 · Concerns exist about whether nurses have sufficient professional competence and knowledge to prescribe medication and whether nurse prescribing ...
  11. [11]
    21 U.S. Code § 829 - Prescriptions - Law.Cornell.Edu
    (A) The term “valid prescription” means a prescription that is issued for a legitimate medical purpose in the usual course of professional practice by— · (B) · (C) ...
  12. [12]
    21 CFR Part 1306 -- Prescriptions - eCFR
    (a) A prescription for a controlled substance to be effective must be issued for a legitimate medical purpose by an individual practitioner acting in the ...1306.21 – 1306.49 · 1306.11 – 1306.15 · Title 21 · General Information<|separator|>
  13. [13]
    Prescription Drugs and Over-the-Counter (OTC) Drugs: Questions ...
    Nov 13, 2017 · Prescribed by a doctor · Bought at a pharmacy · Prescribed for and intended to be used by one person · Regulated by FDA through the New Drug ...
  14. [14]
    Rational prescribing: the principles of drug selection - PMC
    Rational prescribing describes a logical approach that includes making a (differential) diagnosis, estimating prognosis, establishing the goals of therapy, ...
  15. [15]
    Rational Prescribing & Prescription Writing - AccessPharmacy
    Make a specific diagnosis: · Consider the pathophysiologic implications of the diagnosis: · Select a specific therapeutic objective: · Select a drug of choice: ...
  16. [16]
    Ten principles of good prescribing
    May 10, 2017 · Be clear about the reasons for prescribing · Take into account the patient's medication history before prescribing · Take into account other ...
  17. [17]
    Principles of Conservative Prescribing - JAMA Network
    Jun 13, 2011 · These principles urge clinicians to (1) think beyond drugs (consider nondrug therapy, treatable underlying causes, and prevention); (2) ...
  18. [18]
    Promoting rational use of medicines
    Oct 2, 2005 · Rational use of medicines requires that patients receive medications appropriate to their clinical needs, in doses that meet their own individual requirements.
  19. [19]
    Prescribing & Dispensing Drugs & Devices | AMA-Code
    Physicians should prescribe drugs, devices, and other treatments based solely on medical considerations, patient need, and reasonable expectations of ...
  20. [20]
    Rational prescribing: the principles of drug selection - ScienceDirect
    Rational prescribing · maximise clinical effectiveness · minimise harms · avoid wasting scarce healthcare resources · respect patient choice.
  21. [21]
    Evidence-Based Prescribing | Circulation: Cardiovascular Quality ...
    The principles of evidence-based medicine suggest that prescribing decisions should be guided by an objective benchmark, namely scientific evidence. Such ...
  22. [22]
    The Role of Evidence-Based Medicine in Rational Drug Use
    EBM makes available relevant therapeutic information based on the best available evidence that can guide prescribers to prescribe rationally.
  23. [23]
    Principles of Prescription Order Writing and Patient Compliance
    The prescription consists of the superscription, the inscription, the subscription, the signa, and the name and signature of the prescriber, all contained on a ...
  24. [24]
    Prescription Writing 101 (with Example Prescriptions)
    Breaking Down the Prescription Format · Patient Identifiers · Drug/Medication · Strength · Amount · Route · Frequency · The “Why” Portion · How Much.
  25. [25]
    How to write prescriptions clearly and concisely - Healio
    Feb 1, 1997 · Prescriber information: The doctor's name, address and phone number should be clearly written (or preprinted) on the top of the prescription ...
  26. [26]
    What are the 7 Components of a Prescription? - Advocate My Meds
    This includes details on how often the medication should be taken, the quantity to be taken at each dose, and any specific administration instructions (e.g., ...
  27. [27]
    How to Write a Prescription: 7 Steps for Safety
    Aug 15, 2018 · Every drug prescription consists of seven parts: the prescriber's information, the patient's information, the recipe (the medication, or Rx), the signature ( ...Missing: standard AMA
  28. [28]
    [PDF] PRESCRIPTION WRITING GUIDELINES
    Tips to Reduce Errors. 1. All prescriptions must be legible and written in black ink. 2. Avoid abbreviations and dangerous dose expressions (see below).
  29. [29]
    [PDF] Dosage and Administration Section of Labeling: Part 1 of 2 - FDA
    1 A fixed-combination drug product (FCDP) is one in which two or more active ingredients are combined at a fixed dosage in a single dosage form. Should ...
  30. [30]
    How Do I Use Prescription Drug Labeling - FDA
    Nov 13, 2024 · Includes the established pharmacological class, chemical name, structural formula, dosage form, route of administration, active and inactive ...
  31. [31]
    [PDF] Dosage and Administration Section of Labeling for Human ... - FDA
    Oct 17, 2022 · For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/regulatory-information/search-fda-guidance- ...
  32. [32]
    Prescription Abbreviations Including Sig - Verywell Health
    Sig: i po bid pc: Your instructions are to take one pill, by mouth, twice each day, after meals. This means you should take this medication right after ...
  33. [33]
    Evaluation of the NCPDP Structured and Codified Sig Format for e ...
    To evaluate the ability of the structure and code sets specified in the National Council for Prescription Drug Programs Structured and Codified Sig Format
  34. [34]
    Generic Drugs: Questions & Answers - FDA
    Mar 16, 2021 · Trademark laws in the United States do not allow a generic drug to look exactly like other drugs already on the market. Generic medicines ...
  35. [35]
    Assessment of Variation in State Regulation of Generic Drug and ...
    Aug 31, 2020 · Each state has drug product selection laws that regulate whether and how pharmacists can substitute prescriptions for brand-name drugs with more ...
  36. [36]
    Pharmacists Not Required to Substitute Generics for Brand-Name ...
    Sep 1, 2020 · Only 19 US states mandate that pharmacists fill prescriptions for brand-name small molecule drugs with generics when available.
  37. [37]
    Generic-Substitution Laws - U.S. Pharmacist
    Jun 19, 2008 · All states in the U.S. have laws addressing generic substitution to one degree or another. There are "positive formulary" states, which identify ...
  38. [38]
    General Clinical Pharmacology Considerations for Pediatric Studies ...
    Sep 7, 2022 · This guidance addresses general clinical pharmacology considerations for conducting studies so that the dosing and safety information for drugs in pediatric ...
  39. [39]
    Special population considerations and regulatory affairs for clinical ...
    FDA “Guidance for Industry” documents and decision trees provide recommendations for medication dosing in special populations (e.g. pregnancy, children, and ...
  40. [40]
    [PDF] Pediatric Information Incorporated Into Human Prescription Drug ...
    The goal of this guidance is to provide recommendations to help ensure that information on the use of prescription drugs in pediatric populations (whether ...
  41. [41]
    Methods Used for Pediatric Dose Selection in Drug Development ...
    This study describes the current experience with pediatric dosing methods from 2012 to 2020 and had 2 primary objectives.
  42. [42]
    The wish of pediatricians: More medications deemed safe for kids
    Jun 21, 2022 · A paucity of drugs approved for children forces doctors to prescribe 'off-label' and figure out doses. New ways to run clinical trials are yielding more ...
  43. [43]
    Considerations for optimal prescribing in older adults - PMC
    This article will demonstrate an approach to assessing select medications commonly taken by older adults.
  44. [44]
    Strategies to Reduce Polypharmacy in Older Adults - StatPearls - NCBI
    Aug 11, 2024 · Healthcare providers should implement strategies such as comprehensive medication reviews, deprescribing unnecessary medications, and using ...
  45. [45]
    Prescribing medicines to older people—How to consider the impact ...
    Ageing is associated with several changes in human organs, which result in altered medication pharmacokinetics and pharmacodynamics.
  46. [46]
    Renal Failure Drug Dose Adjustments - StatPearls - NCBI Bookshelf
    Jul 27, 2024 · In patients with renal impairment, the dosing of renally cleared drugs has to be adjusted based on the patient's actual GFR.Definition/Introduction · Issues of Concern · Nursing, Allied Health, and...
  47. [47]
    Drug Dosing Adjustments in Patients with Chronic Kidney Disease
    May 15, 2007 · Drug dosing errors are common in patients with renal impairment and can cause adverse effects and poor outcomes. Dosages of drugs cleared ...Abstract · Estimating GFR and... · Dosing Adjustments
  48. [48]
    Pregnancy and Lactation Labeling Resources - FDA
    Mar 10, 2025 · The PLLR requires changes to the content and format for information presented in prescription drug labeling in the Physician Labeling Rule (PLR) format.
  49. [49]
    Drugs and Lactation Database (LactMed®) - NCBI Bookshelf - NIH
    The LactMed® database contains information on drugs and other chemicals to which breastfeeding mothers may be exposed.
  50. [50]
    Safe prescribing practices in pregnancy and lactation - PMC
    In general, we do not recommend use for more than 2 days beyond the first trimester. Similar but more limited information is available for ibuprofen (Advil).
  51. [51]
    Practitioners and Prescriptive Authority - StatPearls - NCBI Bookshelf
    MD and DO clinicians are authorized to prescribe medications, including controlled substances. Additionally, physicians can prescribe Schedule II to V ...
  52. [52]
    Mid-Level Practitioners Authorization by State
    Examples of mid-level practitioners include, but are not limited to, health care providers such as nurse practitioners, nurse midwives, nurse anesthetists, ...
  53. [53]
    NP Scope of Practice vs. Independent Practice: What's the Difference?
    Apr 18, 2024 · Today, in 27 states and Washington D.C., NPs have the explicit legal authority to prescribe. In the remaining states, NPs can still write ...Missing: drugs | Show results with:drugs
  54. [54]
    What is a DEA License? The Basics You Need to Know
    Sep 7, 2023 · Typically, a DEA license is needed for physicians, NPs, PAs, pharmacists, optometrists, and dentists who want to work in a medical facility. How ...
  55. [55]
    [PDF] Who is a prescribing practitioner? - FL HealthSource
    465.0276,. F.S. Dispensing practitioners may include: physicians, dentists, certified optometrists, podiatrists, advanced registered nurse practitioners and ...
  56. [56]
  57. [57]
    Nurse practitioner prescribing: an international perspective | NRR
    Oct 30, 2015 · The aim of this paper was to review the current international literature related to NP prescribing and compare the findings to the Australian context.
  58. [58]
    The Barriers to Nurses with Prescriptive Authority in Exercising Their ...
    Aug 6, 2025 · By 2021, 44 countries and regions had granted some form of prescribing authority to nurses, reflecting a global trend to optimize healthcare ...
  59. [59]
    The regulation and practice of midwifery prescribing around the world
    Around the world, many midwives have the authority to prescribe. This is not universal, and barriers often limit the extent to which midwives can exercise this ...
  60. [60]
    [PDF] GUIDELINES ON PRESCRIPTIVE AUTHORITY FOR NURSES 2021
    The purpose of these guidelines is to facilitate a common understanding of nurse prescribing to inform policymakers, educators, regulators, healthcare planners, ...
  61. [61]
    Recommendations to Enhance Accuracy of Prescription/Medication ...
    Conduct both initial and ongoing training of prescribers on accepted standards of practice related to prescription writing processes with the ultimate goal of ...
  62. [62]
    Improving Medication Safety - ACOG
    Writing an incomplete medication order substantially increases the risk of a medication error. The prescriber's signature and identification number should ...
  63. [63]
    [PDF] ISMP List of Error-Prone Abbreviations, Symbols, and Dose ... - ECRI
    They should NOT be used when communicating medical information verbally, electronically, and/or in handwritten applications. This includes internal ...
  64. [64]
    Simple Strategies to Avoid Medication Errors - AAFP
    Avoid problematic abbreviations. The FDA and ISMP in July 2006 embarked on a joint campaign to eliminate the use of potentially confusing abbreviations, symbols ...Introduction · Drug information · Communication · Patient education
  65. [65]
    [PDF] ASHP Guidelines on Preventing Medication Errors in Hospitals
    Nov 8, 2017 · The purpose of these guidelines is to provide the phar- macists with practical recommendations and best practices for preventing and mitigating ...
  66. [66]
    Medication Dispensing Errors and Prevention - StatPearls - NCBI - NIH
    Feb 12, 2024 · This topic delves into the prevalent causes and categories of medication errors and their consequences for patients and the healthcare system.
  67. [67]
    [PDF] FDA and ISMP Lists of Look-Alike Drug Names with Recommended ...
    Since 2008, ISMP has maintained a list of drug name pairs and trios with recommended, bolded tall man (uppercase) letters to help draw.
  68. [68]
    Bad Writing, Wrong Medication | PSNet - AHRQ
    When illegibility raises doubt in a pharmacist's mind, the pharmacist may seek clarification by viewing the EMR, checking with the patient, or telephoning the ...
  69. [69]
    Overview and Examples of Medical Standing Orders - AHRQ
    Standing orders and protocols allow patient care to be shared among non-clinician members of the care team, like medical assistants and nurses. In accordance ...
  70. [70]
    Standing Orders | Center for Excellence in Primary Care - UCSF
    Standing orders and protocols allow patient care to be shared among non-clinician members of the care team, like medical assistants and nurses.
  71. [71]
    What are Standing Orders and Are They Legal?
    A standing order or protocol is a definitive set of treatment guidelines that include definitive orders for drugs and their specified doses.
  72. [72]
    [PDF] SCLetter09-10.pdf - CMS
    Oct 24, 2008 · The use of standing orders must be documented as an order in the patient's medical record and authenticated by the practitioner responsible ...
  73. [73]
    Non Patient Specific Orders and Protocols | Office of the Professions
    However, New York law authorizes RNs to execute written non-patient specific orders and protocols, issued by a physician, physician assistant, or nurse ...
  74. [74]
    Texas Board of Nursing - Practice
    (13) Standing medical orders--Generally applicable orders, which are used as a guide in preparation for and carrying out medical acts or surgical procedures or ...<|separator|>
  75. [75]
    Administer medication without a doctors order? - NSO
    Many facilities have implemented standing orders or practice protocols that nurses can use to provide medications to patients without a direct physician's order ...
  76. [76]
    Developing Standing Orders to Help Your Team Work to the Highest ...
    This standing order allows nurses (LPNs and RNs) to fulfill routine requests for refills and physician orders without having to wait for a physician's approval.
  77. [77]
    15.2 Basic Concepts of Administering Medications – Nursing Skills
    A standing order is also referred to in practice as an “order set” or a “protocol.” Standing orders are standardized prescriptions for nurses to implement to ...
  78. [78]
    42 CFR § 482.23 - Condition of participation: Nursing services.
    (ii) Drugs and biologicals may be prepared and administered on the orders contained within pre-printed and electronic standing orders, order sets, and protocols ...
  79. [79]
    Chapter 15 Administration of Enteral Medications - Nursing Skills
    A standing order is also referred to in practice as an “order set” or a “protocol.” Standing orders are standardized prescriptions for nurses to implement ...<|control11|><|separator|>
  80. [80]
    Cal. Code Regs. Tit. 22, § 76153 - Standing Orders | State Regulations
    "Standing orders" means those orders which are employed or intended to be employed in the absence of specific orders for a specific client.
  81. [81]
    The Controlled Substances Act - DEA.gov
    The Controlled Substances Act (CSA) places all substances which were in some manner regulated under existing federal law into one of five schedules.
  82. [82]
    Controlled Substance Schedules - DEA Diversion Control Division
    Drugs and other substances that are considered controlled substances under the Controlled Substances Act (CSA) are divided into five schedules. An updated and ...
  83. [83]
    Federal Controlled Substances Act - NIH
    There are no federal quantity limits on Schedule II prescriptions. In addition, there is no federal time limit on when a Schedule II prescription must be filled ...
  84. [84]
    Registering with the DEA and Prescribing Controlled Substances
    Any dentist who prescribes controlled substances in Schedules II, III, IV, or V must register with the Drug Enforcement Administration (DEA) every three years.
  85. [85]
    New DEA training requirement: who has to do it, and how to get it done
    Jul 5, 2023 · The Drug Enforcement Administration (DEA) recently started requiring a new eight-hour training aimed at preventing substance use disorder.
  86. [86]
    [PDF] CMS EPCS Q&A Document for the March 2025 Webinar
    Aug 22, 2025 · The 2025 EPCS requirement is that prescribers must electronically prescribe at least 70% of their qualifying Schedule II-V controlled substance ...
  87. [87]
    Third Temporary Extension of COVID-19 Telemedicine Flexibilities ...
    Nov 19, 2024 · A third extension of telemedicine flexibilities for the prescribing of controlled medications, through December 31, 2025.
  88. [88]
    [PDF] The International Drug Control Conventions: REVISED EDITION 2013
    The present publication contains the texts of the three main international drug control conventions: the Single Convention on Narcotic Drugs of 1961.
  89. [89]
    Drug Conventions - United Nations Office on Drugs and Crime
    The Commission on Narcotic Drugs is mandated to decide on the scope of control of substances under the three International Drug Control Conventions.
  90. [90]
    Understanding Unapproved Use of Approved Drugs "Off Label" - FDA
    Feb 5, 2018 · Unapproved use of an approved drug is often called “off-label” use. This term can mean that the drug is:
  91. [91]
    Prescribing “Off-Label”: What Should a Physician Disclose?
    Off-label prescribing is a common and legal practice in medicine. This practice is justified when scientific evidence suggests the efficacy and safety of a ...
  92. [92]
    Ten Common Questions (and Their Answers) About Off-label Drug ...
    Pharmaceutical companies are not allowed to promote their medications for an off-label use, which has lead to several large settlements for illegal marketing.
  93. [93]
    Off-Label Use vs Off-Label Marketing of Drugs: Part 1
    Feb 27, 2023 · Off-label prescriptions for drugs are common, occurring overall in 21% to 32.3% of prescriptions overall. Prevalence of off-label prescribing ...
  94. [94]
    Off-Label Use of Prescription Drugs | Congress.gov
    Physicians, therefore, may prescribe an FDA-approved drug for indications that FDA has not reviewed for safety and effectiveness. Those uses, furthermore, are ...
  95. [95]
    Drug, Patient, and Physician Characteristics Associated With Off ...
    Apr 16, 2012 · Results The prevalence of off-label use was 11.0%; of the off-label prescriptions, 79.0% lacked strong scientific evidence. Off-label use was ...
  96. [96]
    Off-label Drug Use and Adverse Drug Events in Adults - JAMA Network
    The rate of ADEs for off-label use (19.7 per 10 000 person-months) was higher than that for on-label use (12.5 per 10 000 person-months) (adjusted hazard ratio ...<|separator|>
  97. [97]
    The Law and Practice of Off-Label Prescribing and Physician ...
    Sep 1, 2025 · We review the relevant laws and regulations pertaining to off-label prescription and promotion, as well as the possible legal consequences.
  98. [98]
    21 CFR Part 312 -- Investigational New Drug Application - eCFR
    (a) A sponsor shall submit an IND to FDA if the sponsor intends to conduct a clinical investigation with an investigational new drug that is subject to § 312.2( ...
  99. [99]
    Investigational New Drug Applications (INDs) - Determining Whether ...
    Nov 18, 2020 · This guidance describes when an IND is required, specific situations in which an IND is not required, and a range of issues that, in FDA's ...
  100. [100]
    Expanded Access - FDA
    Sep 8, 2025 · Expanded access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational ...
  101. [101]
    Expanded Access to Investigational Drugs for Treatment Use - FDA
    Since 2017, FDA has received additional questions concerning implementation of the regulatory and statutory requirements of expanded access to investigational ...
  102. [102]
    Overview of FDA's Expanded Access Program for Investigational ...
    Expanded access, also called “compassionate use,” provides a pathway for patients to gain access to investigational drugs, biologics, and medical devices.
  103. [103]
    Global, regional, and national consumption of controlled opioids
    Since 1961, most opioids have been internationally controlled under the United Nations (UN) Single Convention on Narcotic Drugs, amended by the 1972 Protocol.
  104. [104]
    Nurse prescribing of medicines in 13 European countries - PMC
    Dec 9, 2019 · A total of 13 countries have adopted laws on nurse prescribing, of which 12 apply nationwide (Cyprus, Denmark, Estonia, Finland, France, Ireland, Netherlands, ...
  105. [105]
    Nurse prescribing of medicines in 13 European countries
    Dec 9, 2019 · A total of 13 countries have adopted laws on nurse prescribing, of which 12 apply nationwide (Cyprus, Denmark, Estonia, Finland, France, Ireland, Netherlands, ...
  106. [106]
    Pharmacists as independent prescribers in community pharmacy
    The countries where pharmacist can prescribe independently include the United Kingdom, the United States, Canada, Australia, Poland, Switzerland, and Denmark.
  107. [107]
    How do pharmacists in other countries prescribe? - Medical Republic
    Sep 27, 2022 · The Guild cites three countries as examples of places with successful pharmacist-led prescribing: New Zealand, the UK and Canada.
  108. [108]
    Prescription drugs have different rules in different countries | Blog
    * Prescription drug regulations differ globally ... global prescription differences is each country's healthcare system and the accessibility of the substances.
  109. [109]
    [PDF] Classifications of Controlled Substances: Insights from 23 Countries
    Jan 14, 2013 · The purpose of this study was to describe the classification systems for controlled substances in 23 countries and make comparisons. From this ...
  110. [110]
    WHO unveils new guideline to improve global access to controlled ...
    May 26, 2025 · It is designed to support countries in ensuring safe, equitable and affordable access to essential controlled medicines which are critical for ...
  111. [111]
    The effect of electronic prescription systems on pharmacy ... - Nature
    Jul 27, 2025 · While developed countries report utilization rates of 80–90%, only 30–40% of pharmacies in developing countries have implemented such systems.
  112. [112]
    Presenting a prescription in another EU country - European Union
    You can ask your doctor to give you a prescription to use in another EU country, also known as a "cross-border prescription".
  113. [113]
    Variation in the prescription drugs covered by health systems across ...
    We sought to synthesize methods and findings from published studies of formulary variation across health systems in high-income countries.
  114. [114]
    International Variation in Drug Usage: An Exploratory Analysis of the ...
    International drug usage variations are due to disease burden, health system factors, reimbursement, access to diagnosis, and treatment, with no single cause.
  115. [115]
    Where did the Rx symbol come from? - History.com
    May 7, 2014 · The world's first recorded prescriptions were etched on a clay tablet in Mesopotamia around 2100 B.C., while the first drugstores were ...
  116. [116]
    History of the Pharmacy - Ancient Remedies to Modern Medicine
    Nov 27, 2024 · The first written records of medicine and pharmacy come from Mesopotamia around 2100 BCE. Clay tablets detailed the preparation of herbal ...Missing: origins | Show results with:origins<|separator|>
  117. [117]
    03_Ebers Papyrus - Universitätsbibliothek Leipzig
    It contains nearly 900 prescriptions and educational texts concentrating on general and internal medicine. It lists about 80 medical conditions, including heart ...
  118. [118]
    Traditional ancient Egyptian medicine: A review - PMC - NIH
    Jun 19, 2021 · Prescriptions for cosmetic use have been mentioned also in several Egyptian papyri, for instance, these sentences were written in the Ebers ...
  119. [119]
    [PDF] Types of Medicines in the Hippocratic Corpus
    The use of drugs to influence the functions of the human body is believed to be known since the early beginning of the human presence on earth. Many.
  120. [120]
    Pharmacology - The Empire's Physician
    Galen's pharmacopeia (a written list of medications and their effects) was not the first of the ancient world: he built on a long-established tradition. Pliny ...
  121. [121]
    Avicenna: the Persian polymath who shaped modern science ...
    Sep 29, 2020 · Avicenna's Canon brilliantly synthesises Islamic medicine with that of Hippocrates (460 – 370 BC) and Galen (129 – 200 AD). There are also ...
  122. [122]
    The Air of History (Part II) Medicine in the Middle Ages - PMC
    Medicine during the Middle Ages was composed of a mixture of existing ideas from antiquity and spiritual influences.
  123. [123]
    Evidence for the Continued Use of Medieval Medical Prescriptions ...
    This article examines a fifteenth-century remedy book, Oxford, Bodleian Library, Rawlinson c. 299, and describes its collection of 314 medieval medical ...
  124. [124]
    Milestones in US Food and Drug Law - FDA
    Jan 30, 2023 · 1800-1899: FDA Milestones ; 1820, Eleven physicians meet in Washington, D.C., to establish the U.S. Pharmacopeia, the first compendium of ...
  125. [125]
    The History of Medicine Quality - US Pharmacopeia (USP)
    In response to public outcry, Congress declared in the 1938 Food, Drug and Cosmetic Act that all medicines sold in the U.S. must meet applicable USP quality ...
  126. [126]
    [PDF] Milestones of Drug Regulation in the United States - FDA
    Jun 30, 2025 · 1951 Durham-Humphrey Amendment defines the kinds of drugs that cannot be used safely without medical supervision and restricts their sale to ...
  127. [127]
    40 Years of Hatch-Waxman: What is the Hatch-Waxman Act? | PhRMA
    Sep 19, 2024 · The Hatch-Waxman Act was able to facilitate the rapid growth in generic uptake and maintain incentives for innovation.
  128. [128]
    [PDF] Patient Counseling—A Pharmacist's Responsibility to Ensure ... - CMS
    OBRA '90 includes three key drug utilization review (DUR) components that impact the practice of pharmacy: prospective drug utilization review, record ...
  129. [129]
    [PDF] History of Prescription Drug Monitoring Programs
    Mar 14, 2018 · The earliest PDMPs were established primarily as enforcement and regulatory tools providing data to officials responsible for enforcing drug ...
  130. [130]
    The Evolution of the PDMP | Pharmacy Times
    Jul 26, 2018 · PDMPs continued to grow through the 1990s and early 2000s, with 70% of program establishments occurring in the first 15 years of the 21st ...
  131. [131]
    A Political History of Medicare and Prescription Drug Coverage - PMC
    This article examines the history of efforts to add prescription drug coverage to the Medicare program. It identifies several important patterns in policymaking ...
  132. [132]
    E-Prescribing - CMS
    Sep 10, 2024 · The inclusion of electronic prescribing in the Medicare Modernization Act (MMA) of 2003 gave momentum to the movement, and the July 2006 ...
  133. [133]
    E-Prescribing: History, Issues, and Potentials - PMC - PubMed Central
    This paper examines the history and selected issues in the rise of E-RX by a review of salient literature, interviews, and field observations in Pharmacy.
  134. [134]
    Electronic Prescribing: Improving the Efficiency and Accuracy ... - NIH
    The HITECH Act of 2009 proposed that eligible healthcare providers throughout the United States have access to EHRs and use them according to the standards for ...
  135. [135]
    U.S. Achieves Major Milestones In E-Prescribing - Surescripts
    Apr 22, 2009 · Prescriptions routed electronically more than doubled from 29 million in 2007 to 68 million in 2008. • By the end of 2008, increased ...
  136. [136]
    Revolutionizing Health Care: The Evolving Path of E-Prescriptions
    94% of all prescriptions in the United States were electronically filled in 2021, and 92% of prescribers have adopted e-prescribing methods.
  137. [137]
    Electronic Prescriptions for Controlled Substances (EPCS) Q&A
    Answer: DEA regulations require that an EPCS be transferred in its electronic form and may not be converted to another form (e.g., facsimile) for transmission.
  138. [138]
    Revised Regulation Allows DEA-Registered Pharmacies to Transfer ...
    Sep 1, 2023 · The prescription must remain in its electronic form; may not be altered in any way; and the transfer must be communicated directly between two ...
  139. [139]
    Challenges and solutions in implementing electronic prescribing in ...
    Dec 18, 2024 · This study aims to explore the challenges and solutions for implementing electronic prescribing in Iran's health system as a developing country.Missing: timelines rates<|separator|>
  140. [140]
    Electronic Health Records - CMS
    Sep 10, 2024 · Reducing the incidence of medical error by improving the accuracy and clarity of medical records. · Making the health information available, ...
  141. [141]
    (PDF) Benefits and Challenges of Electronic Health Record System ...
    Aug 6, 2025 · Inefficiency of the EHRS that only allowed retrieval of limited medical information of the patients hindered physicians' acceptability of EHRS.<|separator|>
  142. [142]
    Glass | AI Diagnosis & Clinical Decision Support (CDS)
    Our Glass Health AI Clinical Decision Support (CDS) platform is designed to enhance the clinical decision-making processes of clinicians.
  143. [143]
    Elsevier announces expansion to their flagship clinical decision ...
    Mar 4, 2025 · With ClinicalKey AI's seamless integration with the Epic EHR system, clinicians can easily move between the patient's EHR and the latest ...
  144. [144]
    Exploring the impact of artificial intelligence integration on ...
    Prescription validation tools led to a 55 % reduction in prescribing errors. AI-driven alert filtering decreased non-actionable alerts by 45 %.
  145. [145]
    Clinical and Operational Applications of Artificial Intelligence ... - NIH
    Mar 7, 2025 · Community pharmacies have seen a 40% increase in drug adherence and a 55% reduction in missed prescription refills since implementing artificial intelligence ( ...
  146. [146]
    Utilization of Artificial Intelligence in Reducing the Incidence of ...
    Research has shown that AI has prevented MEs through personalized reminders, confirming medication identification, and alert systems in case of drug‐to‐drug ...
  147. [147]
    Clinical decision support using pseudo-notes from multiple streams ...
    Jul 2, 2025 · In this work, we introduce the Multiple Embedding Model for EHR (MEME), a deep learning framework for clinical decision support that operates over ...
  148. [148]
    use of artificial intelligence to optimize medication alerts generated ...
    Apr 19, 2024 · The then studies included show that AI has the capacity to adequately reduce alert burden and identify inappropriate prescriptions, but the ...Background and significance · Methods · Results · Discussion
  149. [149]
    Detecting clinical medication errors with AI enabled wearable cameras
    Oct 22, 2024 · We present the first wearable camera system to automatically detect potential errors, prior to medication delivery.
  150. [150]
    Artificial intelligence in healthcare: transforming patient safety with ...
    Jan 7, 2025 · In managing medication errors, AI and machine learning have shown promise in decision support for prescription accuracy and error prevention ...<|control11|><|separator|>
  151. [151]
    The Top Challenges in E-Prescribing and How Modern Systems Are ...
    Jun 26, 2025 · Modern e-prescribing tackles errors, security, compliance & drug monitoring, enhancing safety, connectivity & ROI for providers.
  152. [152]
    Barriers and facilitators of health professionals in adopting digital ...
    Jan 17, 2024 · Alert fatigue, the time consumed, and the ease of use were common technical barriers and facilitators among primary care and hospitals (Table S5) ...
  153. [153]
    Challenges and advantages of electronic prescribing system
    May 30, 2024 · Usability issues: The e-prescribing system might not be user-friendly or intuitive, leading to difficulties in adoption among healthcare ...
  154. [154]
    Challenges and Solutions in Implementing Electronic Prescribing
    Sep 18, 2024 · Systemic challenges included infrastructure problems (18 cases), user interface (UI) issues (14 cases), and database issues (10 cases). The ...
  155. [155]
    Benefits and Risks of AI in Health Care: Narrative Review - PMC - NIH
    This study aims to evaluate the advantages and drawbacks of incorporating AI in health care. This assessment centers on the potential biases in AI algorithms, ...
  156. [156]
    Risks and remedies for artificial intelligence in health care | Brookings
    Nov 14, 2019 · Several risks and challenges emerge, including the risk of injuries to patients from AI system errors, the risk to patient privacy of data acquisition and AI ...
  157. [157]
    7 Challenges of AI Integration in Healthcare and Their Remedies
    Apr 16, 2025 · Obstacles include setting an AI strategy, dealing with fragmented data, and addressing ethics, security and compliance.
  158. [158]
    Revolutionizing healthcare: the role of artificial intelligence in clinical ...
    Sep 22, 2023 · Overcoming challenges like data quality, privacy, bias, and the need for human expertise is essential for responsible and effective AI ...
  159. [159]
    Recent Advancements in Emerging Technologies for Healthcare ...
    The subsequent phase in healthcare is to seamlessly consolidate these emerging technologies such as IoT-assisted wearable sensor devices, AI, and Blockchain ...
  160. [160]
    Optimising ePrescribing in hospitals through the interoperability of ...
    Oct 11, 2023 · Our thematic analysis identified 4 main drivers for increasing ePrescribing systems interoperability: (1) improving patient safety (2) improving integration & ...
  161. [161]
    8 Medical Technology Trends to Watch in 2025 - AMN Healthcare
    Oct 28, 2024 · 1. Integration of AI in Healthcare · 2. Hyper-Personalized Medicine · 3. Data-Driven Healthcare Transformation · 4. Blood Testing Reimagined · 5.
  162. [162]
    Changes in Opioid Prescribing in the United States, 2006–2015 - CDC
    Jul 7, 2017 · In the United States, annual opioid prescribing rates increased from 72.4 to 81.2 prescriptions per 100 persons from 2006 to 2010, were constant ...
  163. [163]
    CDC Clinical Practice Guideline for Prescribing Opioids for Pain
    Nov 4, 2022 · This clinical practice guideline expands and updates the 2016 CDC Opioid Prescribing Guideline to provide evidence-based recommendations for ...
  164. [164]
    Drug and Opioid-Involved Overdose Deaths — United States, 2017 ...
    Mar 20, 2020 · Prescription opioid-involved death rates decreased by 13.5% from 2017 to 2018. Rates decreased in males and females, persons aged 15–64 years, ...<|separator|>
  165. [165]
    [PDF] Uncovering the Opioid Epidemic | CDC
    Drug overdose deaths have been increasing in the United States since the 1990's, mostly due to the use of opioids. More than 500,000 people in the United States ...
  166. [166]
    Opioid Dispensing Rate Maps | Overdose Prevention - CDC
    Nov 7, 2024 · The overall national opioid dispensing rate declined steadily from a rate of 46.8 opioid prescriptions dispensed per 100 persons in 2019 to ...
  167. [167]
    About Prescription Opioids | Overdose Prevention - CDC
    Jun 10, 2025 · Fast Facts: In 2023, nearly 8.6 million Americans 12 years and older reported misusing prescription opioids in the past year. 5.
  168. [168]
    Benzodiazepine Use and Misuse Among Adults in the United States
    Feb 1, 2020 · Adults 50–64 had the highest prescribed use (12.9%). Those 18–25 had the highest misuse (5.2%), while adults ≥65 had the lowest (0.6%). Misuse ...
  169. [169]
    Trends in Nonfatal and Fatal Overdoses Involving Benzodiazepines
    Aug 27, 2021 · From April–June 2019 to April–June 2020, prescription and illicit benzodiazepine-involved overdose deaths increased 21.8% and 519.6%, ...
  170. [170]
    Disrupted Access to Prescription Stimulant Medications Could ...
    Jun 13, 2024 · Misuse of prescription stimulants, particularly among young adults, is a growing public health concern, with 14.5% of college students reporting ...
  171. [171]
    Study Shows Nearly 300% Increase in ADHD Medication Errors
    Sep 18, 2023 · According to the study, the annual number of ADHD-related medication errors increased 299% from 2000 to 2021.
  172. [172]
    Abuse of Medications Employed for the Treatment of ADHD
    Prescription stimulants. Survey results indicated that 14.3% of respondents abused prescription stimulants (Figure 1A). Of those who abused prescription ...
  173. [173]
    Antibiotic Use in the United States - CDC
    Sep 15, 2025 · Prescribing trends. Most human antibiotic use (85-95%) occurs in outpatient settings. 1; At least 28% of antibiotics prescribed in outpatient ...At A Glance · Outpatient Settings · Antibiotic Prescribing...
  174. [174]
  175. [175]
    Addressing Antibiotic Overuse in the Outpatient Setting - NIH
    Studies estimate that more than 12% of all ambulatory visits in the U.S. result in an antibiotic prescription, and 23–30% of these prescriptions are “ ...
  176. [176]
    CDC Research Shows Antibiotic Prescribing Rates Decreased ...
    The studies show a 33% decrease in antibiotic prescribing in outpatient settings during the COVID-19 pandemic and an overall decrease in antibiotic use among ...
  177. [177]
    The Opioid Epidemic: A Review of the Contributing Factors ... - NIH
    Jul 10, 2023 · Overprescribing opiates and opioids, lack of education and opportunity, and being unmarried or divorced were some of the identified contributing factors to ...
  178. [178]
    The cost of influence: How gifts to physicians shape prescriptions ...
    This paper investigates the influence of gifts – monetary and in-kind payments – from drug firms to US physicians on prescription behavior and drug costs.
  179. [179]
    Are Financial Payments From the Pharmaceutical Industry ...
    Apr 11, 2025 · Payments were associated with increased prescribing of the paying company's drug, increased prescribing costs, and increased prescribing of ...<|control11|><|separator|>
  180. [180]
    Effect of pharmaceutical promotion and incentives offered by ...
    May 22, 2024 · A meta-analysis of studies conducted in six countries found that PP influences physicians' prescribing behaviors resulting in increased ...
  181. [181]
    Association between physicians' interaction with pharmaceutical ...
    A meta-analysis of six of these studies found a statistically significant association between exposure and physicians' prescribing behaviors (OR = 2.52; 95% CI ...
  182. [182]
    Industry payments to US neurologists related to multiple sclerosis ...
    Aug 26, 2025 · While the median amount per physician was US$779 (IQR, US$188–US$2587), US$155.7 million (95.2%) accrued to the top 10% of payment recipients.
  183. [183]
    Direct-to-Consumer Drug Advertisement and Prescribing Practices
    DTCA increases prescription requests, increases the likelihood of prescription, and increases both appropriate and inappropriate prescribing.
  184. [184]
    [PDF] Impact of Direct-to-Consumer Advertising on Prescription Drug ... - KFF
    DTC advertising accounted for 12% of drug spending growth in 2000, with each dollar spent yielding $4.20 in sales. Promotional spending more than doubled from ...
  185. [185]
    Industry marketing payments to physicians and prescription patterns ...
    This study aims to evaluate associations between industry-sponsored meal payments to physicians and their prescribing patterns for sacubitril/valsartan in the ...
  186. [186]
    Pharmaceutical policies: effects of financial incentives for prescribers
    Although financial incentives are considered an important element in strategies to change prescribing patterns, limited evidence of their effects can be found.
  187. [187]
    Interaction between physicians and the pharmaceutical industry
    Almost all published studies reported a positive relationship between payments and changes in physician prescribing behavior (1, 6, 7, 18).
  188. [188]
    Public Reporting of Pharmaceutical and Medical Device Industry ...
    In 2022, about one third of all prescribing clinicians received at least 1 payment from a pharmaceutical or medical device company (Table 2). The median value ...
  189. [189]
    Prescription Requirements and Patient Autonomy - NIH
    In general, competent adult patients should be treated as autonomous decision-makers who have the legal and ethical right to make informed decisions about the ...
  190. [190]
    Prior Authorizations and the Adverse Impact on Continuity of Care
    Apr 2, 2025 · Prior authorizations result in 94% of patients experiencing delays in care and 78% abandoning treatment altogether. Prior authorizations ...
  191. [191]
    Prior authorization delays care—and increases health care costs
    Aug 12, 2024 · Among the physicians surveyed, 79% said that a prior authorization delay or denial at least sometimes leads to a patient paying out of pocket ...
  192. [192]
    Prior Authorization and Association With Delayed or Discontinued ...
    Introduction of a new prior authorization policy on an established drug regimen is associated with increased probability of discontinued and delayed care.
  193. [193]
    FDA Approvals Are a Matter of Life and Death - PMC - NIH
    One significant cause of this delay is the FDA and a decades-old regulatory process that is outmoded and needlessly long. Advances in science and new ...
  194. [194]
    Delays in Drug Approval Are Deadly, Highlighting the Need for ...
    Oct 25, 2015 · Worldwide, 1 life-year was lost for every 12 seconds of delay. He broke the analysis down for individual drugs and demonstrated that ...
  195. [195]
    [PDF] 703 - RFS 006 Upholding Physician Autonomy in Evidence-Based ...
    May 6, 2024 · “Off-label” drug use: an FDA regulatory term, not a negative implication of its medical use. Int J. Impot Res. 2008;20(2):135-144. 3. US FDA ...
  196. [196]
    “Not Allowed to Be Compassionate”: Chronic Pain, the Overdose ...
    Dec 18, 2018 · In some cases, this desire to cut back on opioid prescribing translated to doctors tapering patients off their medications without patient ...
  197. [197]
    Understanding Links among Opioid Use, Overdose, and Suicide
    Jan 2, 2019 · The use of potentially lethal drugs such as opioids has a clear, direct relationship to the risk of unintentional overdose.
  198. [198]
    Right to Try Requests and Oncologists' Gatekeeping Obligations
    Oct 15, 2019 · The premise of Right to Try is that regulatory bodies should not be party to doctor-patient decisions about how to respond to life-threatening disease.
  199. [199]
    Serious Risks And Few New Benefits From FDA-Approved Drugs
    Jul 6, 2015 · Over 90 percent of new drugs approved by the FDA and the European Medicines Agency (EMA) offer few or no advantages over existing drugs to offset their risks ...Missing: delays mortality
  200. [200]
    National trends in prescription drug expenditures and projections for ...
    Jul 8, 2024 · Results: In 2023, overall pharmaceutical expenditures in the US grew 13.6% compared to 2022, for a total of $722.5 billion. Utilization (a 6.5% ...
  201. [201]
    Prescription Drug Prices in the U.S. Are 2.78 Times Those in Other ...
    Feb 1, 2024 · “We find that the gap is widening for name-brand drugs, while U.S. prices for generic drugs are now proportionally lower than our earlier ...
  202. [202]
    Changes in the List Prices of Prescription Drugs, 2017-2023 | ASPE
    Oct 6, 2023 · From January 2022 to January 2023, the average price change for single source drugs was 7.4 percent ($958) while the average increase for multi- ...
  203. [203]
    Research and Development in the Pharmaceutical Industry
    Apr 8, 2021 · In recent studies, estimates of the average R&D cost per new drug range from less than $1 billion to more than $2 billion per drug. Those ...
  204. [204]
    The Impact of Patent Expiry on Drug Prices: A Systematic Literature ...
    Drug prices decrease significantly after patent expiry, with price ratios ranging from 6.6% to 66% 1-5 years after, but the extent varies greatly.
  205. [205]
    High R&D Isn't Necessarily Why Drugs Are So Expensive
    Sep 26, 2022 · The researchers compared data on R&D costs with drug prices. They found no relationship between what pharmaceutical companies spend on R&D and ...
  206. [206]
    A Third of Americans Don't Fill Prescriptions Due to Cost - GoodRx
    27% of Americans don't fill prescriptions due to cost, with 28% having prescriptions sent to the pharmacy but not filled. 20% can't fill due to insurance not ...
  207. [207]
    Public Opinion on Prescription Drugs and Their Prices - KFF
    Oct 4, 2024 · KFF research has consistently found prescription drug costs to be an important health policy area of public interest and concern.
  208. [208]
    Do lower prices make generic medications the top choice for ... - Tebra
    Jan 6, 2025 · On average, generic medications cost approximately 79% less than brand-name medications. When choosing between generic and brand-name ...
  209. [209]
    U.S. Consumers Overpay for Generic Drugs - May 31, 2022
    May 31, 2022 · Generics account for only a slice—about 18%—of overall U.S. retail prescription drug expenditures, which reached nearly $350 billion in 2020.5,6 ...Missing: name | Show results with:name<|control11|><|separator|>
  210. [210]
    Report: 2023 U.S. Generic and Biosimilar Medicines Savings Report
    The report finds the average sales price for biosimilars is on average 50% less than the reference brand biologic price was at the time of biosimilar launch.
  211. [211]
    Medicare Prescription Drug Costs | Commonwealth Fund
    Feb 10, 2025 · High drug costs cause Medicare patients to skip prescriptions, delay care, and use cost-cutting strategies. Providers see patients overwhelmed ...
  212. [212]
    [PDF] Pharmacy Benefit Managers: The Powerful Middlemen Inflating ...
    I. EXECUTIVE SUMMARY. This Interim Report is part of an ongoing study by the Federal Trade Commission (“FTC” or the. “Commission”) of pharmacy benefit ...
  213. [213]
    [PDF] The Role of Pharmacy Benefit Managers in Prescription Drug Markets
    Jul 9, 2024 · Drug pricing and pharmacy reimbursement: Limiting PBMs' use of manufacturer rebates and their ability to pay pharmacies less than they ...
  214. [214]
    The Role of Pharmacy Benefit Managers and Skyrocketing Cost of ...
    PBMs act as intermediaries, adjudicate claims, set formularies, negotiate pricing, and use practices like spread pricing to increase profits, despite claiming ...
  215. [215]
    What are pharmacy benefit managers (PBMs) and why we need ...
    Aug 7, 2025 · Pharmacy benefit managers (PBMs) manage prescription drug plan (PDP) benefits for insurers and/or employers. PBMs are “middlemen” in the ...
  216. [216]
    US Drug Pricing and Reimbursement: Players, Payers, PBMs, and ...
    This article examined interactions between patient health insurance prescription benefits, pharmacies, and pharmacy benefit managers (PBMs), and their ...
  217. [217]
    [PDF] 2024 AMA prior authorization physician survey
    As this year's findings demonstrate, the PA process continues to have a devastating effect on patient outcomes, physician burnout and employee productivity. In ...Missing: filling | Show results with:filling
  218. [218]
    A Current Snapshot of the Medicare Part D Prescription Drug Benefit
    Oct 7, 2025 · This brief provides an overview of the Medicare Part D prescription drug benefit, including current data on plan availability, enrollment, ...Missing: dynamics | Show results with:dynamics
  219. [219]
    NHE Fact Sheet - CMS
    Jun 24, 2025 · Out of pocket spending grew 7.2% to $505.7 billion in 2023, or 10 percent of total NHE. Other Third Party Payers and Programs and Public Health ...
  220. [220]
    Prescription Drugs | Health Policy Institute | Georgetown University
    The average annual out-of-pocket prescription drug expenditure for Medicare beneficiaries is $581, compared to $297 for those on Medicaid and $156 for those ...A Vital Component Of Health... · Cost Affects Compliance · Medicaid Pharmacy Policy...<|control11|><|separator|>
  221. [221]
    [PDF] Prescription Drug Spending, Pricing Trends, and Premiums in ...
    Nov 6, 2024 · National Sales Perspective data give gross prices received by the manufacturer while sources such as medical claims data or the MEPS-HC give ...
  222. [222]
    FAQs about the Inflation Reduction Act's Medicare Drug Price ... - KFF
    The Inflation Reduction Act requires CMS to consider certain manufacturer-specific factors and information about therapeutic alternatives to selected drugs in ...
  223. [223]
    Prescription Drug Price Reforms Impact - Commonwealth Fund
    Nov 29, 2023 · Legislative solutions to prescription drug prices were slow to materialize until the Inflation Reduction Act changed how Medicare pays for ...Missing: outcomes | Show results with:outcomes
  224. [224]
    Explaining the Prescription Drug Provisions in the Inflation ... - KFF
    Jan 24, 2023 · CBO estimates that the drug pricing provisions in the law will reduce the federal deficit by $237 billion over 10 years (2022-2031). The ...Missing: outcomes | Show results with:outcomes
  225. [225]
    Policy Options to Reduce Prescription Drug Costs - Stanford Medicine
    Moreover, drug shortages have reached their highest levels in a decade, with an average of 301 drugs in shortage per quarter in 2023, a 13% increase from the ...
  226. [226]
    Report shows decreases in opioid prescribing, increase in overdoses
    Sep 21, 2021 · Opioid prescriptions have decreased (PDF) by 44.4 percent between 2011-2020, including a 6.9 percent decrease from 2019-2020. Along with the ...<|separator|>
  227. [227]
    Evaluation of State Policy Interventions Targeting the US Opioid ...
    Feb 12, 2021 · State policies were associated with a reduction in known indicators of prescription opioid misuse as well as deaths from prescription opioid overdose.
  228. [228]
    The effects of opioid policy changes on transitions from prescription ...
    Jul 21, 2022 · They described needing to take more POs or switched to heroin or fentanyl as their tolerance increased. As more policies were passed to limit ...
  229. [229]
    Recent changes in trends of opioid overdose deaths in North America
    Aug 31, 2020 · Recent evidence suggests that although opioid overdose deaths have been increasing in the United States, opioid prescribing has declined [17].
  230. [230]
    DEA and HHS Extend Telemedicine Flexibilities through 2025
    Nov 15, 2024 · With the end of 2024 quickly approaching, DEA, jointly with HHS, has extended current telemedicine flexibilities through December 31, 2025.Missing: post- | Show results with:post-
  231. [231]
    Prescribing controlled substances via telehealth
    Nov 20, 2024 · Telemedicine flexibilities regarding prescription of controlled medications include: A DEA-registered practitioner can prescribe a schedule II-V ...
  232. [232]
    State Telehealth Laws and Reimbursement Policies Report, Fall 2024
    Since Fall 2023, several states have implemented new rules around prescribing via telehealth, especially for controlled substances. Examples can be found in the ...
  233. [233]
    The Future of Telemedicine Prescribing Comes Into Focus
    Feb 3, 2025 · The new regulations permit DEA-registered practitioners to prescribe up to an initial six-month supply of buprenorphine pursuant to an audio- ...<|control11|><|separator|>